ARCHIVES

ODAC Nixes Abraxane for Adjuvant Breast Cancer, While Genasense Falls Victim to Its Randomized Trial.

This article is from The Cancer Letter archive.

Vol. 32 No. 31 | September 8, 2006

Download PDF Visit The Full Archive

Related Articles

Aflibercept Improves Overall Survival In Second-Line Colorectal Cancer Setting

April 29, 2011

Some Of Show’s Screening Messages Not Widely Accepted.

September 12, 2008

Klausner To Revamp NCI Budget Process To Make Categories Mean What They Say

December 8, 1995

In Brief: Hopkins Wins SPORE in Gastointenstinal Cancers; Nurses Group Calls For Proposals

January 21, 1994

Doubling Of Cancer Research Budget To Take Eight Years Under Obama Plan

May 15, 2009

Bunn To Succeed Norton As ASCO President, Tempero Is President-Elect

April 26, 2002